http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Lorz, Laura Rojas,Kim, Donghyun,Kim, Mi-Yeon,Cho, Jae Youl The Korean Society of Ginseng 2020 Journal of Ginseng Research Vol.44 No.3
Background: BIOGF1K, a fraction of Panax ginseng, has desirable antimelanogenic, anti-inflammatory, and antiphotoaging properties that could be useful for treating skin conditions. Because its potential positive effects on allergic reactions in skin have not yet been described in detail, this study's main objective was to determine its efficacy in the treatment of atopic dermatitis (AD). Methods: High-performance liquid chromatography was used to verify the compounds in BIOGF1K, and we used the (3-4-5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide method to determine its cytotoxicity in RBL-2H3 and HMC-1 cell lines. RBL-2H3 cells were induced using both anti-DNP-IgE/DNP-BSA and calcium ionophore (A2187) treatments, whereas HMC-1 cells were induced using A2187 alone. To measure mast cell degranulation, we performed histamine (enzyme-linked immunosorbent assay) and β-hexosaminidase assays. To quantify interleukin (IL)-4, IL-5, and IL-13 levels in RBL-2H3 cells, we performed quantitative polymerase chain reaction (PCR); to quantify expression levels of IL-4 and IL-13 in HMC-1 cells, we used semiquantitative reverse transcription polymerase chain reaction (RT-PCR). Finally, we detected the total and phosphorylated forms of extracellular signal-regulated kinase, p-38, and c-Jun N-terminal kinase proteins by immunoblotting. Results: BIOGF1K decreased the AD response by reducing both histamine and β-hexosaminidase release as well as reducing the secretion levels of IL-4, IL-5, and IL-13 in RBL-2H3 cells and IL-4 and IL-13 in HMC-1 cells. In addition, BIOGF1K decreased MAPK pathway activation in RBL-2H3 and HMC-1 cells. Conclusions: BIOGF1K attenuated the AD response, hence supporting its use as a promising and natural approach for treating AD.
Medicinal potential of Panax ginseng and its ginsenosides in atopic dermatitis treatment
Lorz, Laura Rojas,Kim, Mi-Yeon,Cho, Jae Youl The Korean Society of Ginseng 2020 Journal of Ginseng Research Vol.44 No.1
Atopic dermatitis (AD) is a chronic and relapsing inflammatory disease that affects 1%-20% of people worldwide. Despite affecting many people, AD current treatments, such as corticosteroids and calcineurin inhibitors, have not only harmful secondary effects but are also often ineffective. Therefore, natural nontoxic compounds are on high demand for developing new effective AD treatments. Panax ginseng Meyer has been used traditionally for its promising healing and restorative properties to treat many diseases including skin disorders, reason why in this review we want to explore the research performed with AD and P. ginseng as well as determining its potential for new drug development. Previous researches have shown that P. ginseng has positive effects in AD patients such as lower eczema area and severity index, transepidermal water loss, and immunoglobulin E levels and better quality of sleep. In vivo animal models, as well, have shown positive results to P. ginseng and derived ginsenosides, such as the decrease of transepidermal water loss, immunoglobulin E levels in serum, allergy-related cytokines, and downregulation of NF-κB, MAPK, and Ikaros pathways. All of these previous data suggest that P. ginseng and its derived ginsenosides are undoubtedly a nontoxic effective option to treat AD.
Laura Rojas Lorz,Donghyun Kim,Mi-Yeon Kim,Jae Youl Cho 고려인삼학회 2020 Journal of Ginseng Research Vol.44 No.3
Background: BIOGF1K, a fraction of Panax ginseng, has desirable antimelanogenic, anti-inflammatory, andantiphotoaging properties that could be useful for treating skin conditions. Because its potential positiveeffects on allergic reactions in skin have not yet been described in detail, this study’s main objective wasto determine its efficacy in the treatment of atopic dermatitis (AD). Methods: High-performance liquid chromatography was used to verify the compounds in BIOGF1K, andwe used the (3-4-5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide method to determine itscytotoxicity in RBL-2H3 and HMC-1 cell lines. RBL-2H3 cells were induced using both antieDNP-IgE/DNP-BSA and calcium ionophore (A2187) treatments, whereas HMC-1 cells were induced using A2187alone. To measure mast cell degranulation, we performed histamine (enzyme-linked immunosorbentassay) and b-hexosaminidase assays. To quantify interleukin (IL)-4, IL-5, and IL-13 levels in RBL-2H3 cells,we performed quantitative polymerase chain reaction (PCR); to quantify expression levels of IL-4 and IL-13 in HMC-1 cells, we used semiquantitative reverse transcription polymerase chain reaction (RT-PCR). Finally, we detected the total and phosphorylated forms of extracellular signal-regulated kinase, p-38,and c-Jun N-terminal kinase proteins by immunoblotting. Results: BIOGF1K decreased the AD response by reducing both histamine and b-hexosaminidase releaseas well as reducing the secretion levels of IL-4, IL-5, and IL-13 in RBL-2H3 cells and IL-4 and IL-13 inHMC-1 cells. In addition, BIOGF1K decreased MAPK pathway activation in RBL-2H3 and HMC-1 cells. Conclusions: BIOGF1K attenuated the AD response, hence supporting its use as a promising and naturalapproach for treating AD.
Medicinal potential of Panax ginseng and its ginsenosides in atopic dermatitis treatment
Laura Rojas Lorz,김미연,Jae Youl Cho 고려인삼학회 2020 Journal of Ginseng Research Vol.44 No.1
Atopic dermatitis (AD) is a chronic and relapsing inflammatory disease that affects 1%e20% of peopleworldwide. Despite affecting many people, AD current treatments, such as corticosteroids and calcineurininhibitors, have not only harmful secondary effects but are also often ineffective. Therefore,natural nontoxic compounds are on high demand for developing new effective AD treatments. Panaxginseng Meyer has been used traditionally for its promising healing and restorative properties to treatmany diseases including skin disorders, reason why in this review we want to explore the researchperformed with AD and P. ginseng as well as determining its potential for new drug development. Previous researches have shown that P. ginseng has positive effects in AD patients such as lower eczemaarea and severity index, transepidermal water loss, and immunoglobulin E levels and better quality ofsleep. In vivo animal models, as well, have shown positive results to P. ginseng and derived ginsenosides,such as the decrease of transepidermal water loss, immunoglobulin E levels in serum, allergy-relatedcytokines, and downregulation of NF-kB, MAPK, and Ikaros pathways. All of these previous datasuggest that P. ginseng and its derived ginsenosides are undoubtedly a nontoxic effective option to treatAD.
Laura Rojas Lorz,Donghyun Kim,Mi-Yeon Kim,Jae Youl Cho 고려인삼학회 2020 Journal of Ginseng Research Vol.44 No.3
Background: BIOGF1K, a fraction of Panax ginseng, has desirable antimelanogenic, anti-inflammatory, and antiphotoaging properties that could be useful for treating skin conditions. Because its potential positive effects on allergic reactions in skin have not yet been described in detail, this study’s main objective was to determine its efficacy in the treatment of atopic dermatitis (AD). Methods: High-performance liquid chromatography was used to verify the compounds in BIOGF1K, and we used the (3-4-5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide method to determine its cytotoxicity in RBL-2H3 and HMC-1 cell lines. RBL-2H3 cells were induced using both antieDNP-IgE/ DNP-BSA and calcium ionophore (A2187) treatments, whereas HMC-1 cells were induced using A2187 alone. To measure mast cell degranulation, we performed histamine (enzyme-linked immunosorbent assay) and b-hexosaminidase assays. To quantify interleukin (IL)-4, IL-5, and IL-13 levels in RBL-2H3 cells, we performed quantitative polymerase chain reaction (PCR); to quantify expression levels of IL-4 and IL- 13 in HMC-1 cells, we used semiquantitative reverse transcription polymerase chain reaction (RT-PCR). Finally, we detected the total and phosphorylated forms of extracellular signal-regulated kinase, p-38, and c-Jun N-terminal kinase proteins by immunoblotting. Results: BIOGF1K decreased the AD response by reducing both histamine and b-hexosaminidase release as well as reducing the secretion levels of IL-4, IL-5, and IL-13 in RBL-2H3 cells and IL-4 and IL-13 in HMC-1 cells. In addition, BIOGF1K decreased MAPK pathway activation in RBL-2H3 and HMC-1 cells. Conclusions: BIOGF1K attenuated the AD response, hence supporting its use as a promising and natural approach for treating AD.
Photoaging Protective Effects of BIOGF1K, a Compound-K-Rich Fraction Prepared from Panax ginseng
Yo Han Hong(홍요한),Sang Hee Park(박상희),Nur Aziz(누르 아지즈),Rojas Lorz Laura(로하스 롤스 라우라),Nurinanda Prisky Qomaladewi(누리난다 프리스키 쿠말라데위),Chaoran Song(송차오란),Stephanie Triseptya Hunto(스테파니 트리셉티아 훈토),Jae Youl Cho( 한국약용작물학회 2017 한국약용작물학회 학술대회논문집 Vol.2017 No.2
Anti-melanogenesis nd Skin Protective Activity of Panax ginseng Calyx Ethanol Extract
Sang Yun Han(한상윤),Eun Ji Kim(김은지),Yohan Hong(홍요한),Han Gyung Kim(김한경),Deok Jeong(정덕),Sang Hee Park(박상희),Nurinanda Prisky Qomaladewi,Song Chaoran,Nur Aziz,Rojas Lorz Laura,Jae Youl Cho(조재열) 한국약용작물학회 2019 한국약용작물학회 학술대회논문집 Vol.2019 No.2